Characterisation of the pharmaceutical risk sharing arrangement process in Catalonia

10 August 2021 - Pharmaceutical risk sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines ...

Read more →

2021's first forecast of savings from side agreements

28 June 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...

Read more →

International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market

23 September 2020 - This study aims to summarise the international experience of performance-based risk-sharing arrangements and identify the preconditions for ...

Read more →

The use of risk-sharing contracts in health care: theoretical and empirical assessments

3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...

Read more →

NHS England wants money back guarantee on Orkambi

24 May 2019 - Vertex resisting real-world data proposal. ...

Read more →

Pfizer launches China's first pay for performance model for cancer

26 January 2019 - Pfizer launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The ...

Read more →

EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?

14 September 2018 - The EU’s centralized procedure for the authorization of a new drug is performed by the EMA.  ...

Read more →

Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...

Read more →

For expensive new drugs, biopharma should make money-back guarantees mandatory

2 May 2018 - In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of ...

Read more →

In battle to cut drug prices, outcome-based pricing carries big risks for biopharma

28 March 2018 - In a provocative piece entitled “Trump’s Health Secretary Wants To Transform Healthcare. Can He?”, fellow Forbes contributor, ...

Read more →

A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

13 February 2018 - Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the ...

Read more →

Characteristics of managed entry agreements in Australia

26 December 2017 - Australia relies on managed entry agreements for many medicines added to the national Pharmaceutical Benefits Scheme.  ...

Read more →

Performance-based risk-sharing arrangements: an updated international review

25 September 2017 - Enthusiasm for performance-based risk-sharing arrangements continues but at variable pace across countries. Our objective was to identify ...

Read more →

The art of the deal? Why a money-back guarantee for drugs is a bad idea

17 July 2017 - President Trump likes to boast that he mastered the “art of the deal.” ...

Read more →

Considering the side effects of drug makers’ money back guarantees

10 July 2017 - More than a decade ago, Italy tried a novel approach to help bring down drug costs: ...

Read more →